News

Osteoporosis Medication Developed and Manufactured on Contract has Launched

To be a Socially Trusted Company, and to Achieve a Sustainable Society

To Support Continued Growth of Its Vascular Graft Business and Contribute to Personalised Aortic Therapy

For the Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults

FINIA® Fill and Finish System: A New Automation Solution for the Production and Delivery of Cell and Gene Therapy

MODEL U-SES Study Presented at TCT 2019

Enables the Clinical, Economic, and Patient Benefits Associated with Radial Artery Access

Today on the sidelines of the 74th session of the United Nations General Assembly

Therapeutic Plasma Exchange Innovation Award Aims to Promote Data-Driven Research in Neurology and Nephrology Fields

Capital Investment of 2 Billion Yen in Terumo Yamaguchi D&D for Pre-filled Syringes

Osteoporosis Treatment Formulation Developed by Asahi Kasei Pharma Receives Approval

Contributing to Patients' Pain Management

Committing Investment up to USD 50 Million, to Support Medtech Startups

The Brazilian Association of Lymphoma and Leukemia aims to guarantee universality, equity and integral service for all

First and only non-coated drug-eluting angioplasty balloon that delivers a proprietary bioabsorbable, sustained-release formulation of sirolimus

The WEB-IT pivotal trial highlights positive clinical outcomes with the WEB® Aneurysm Embolization System, the only intrasaccular flow disruptor approved in the United States.

Antoinette Gawin Focuses on Terumo BCT’s Potential to Treat Disease and Play a Greater Role in Cell Therapy and Regenerative Medicine—Serving More Patient

Advanced synthetic bioabsorbable solution controls bleeding during sternotomy procedures and promotes bone growth during post-operative healing1

Goal: Advocate for an Adequate, Safe and Sustainable Blood Supply

Innovative technology improves patient care during cardiopulmonary bypass

Significant milestone achieved for global study likely to change DAPT guidelines

The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysms